Literature DB >> 27857979

Normoxic or hypoxic adaptation in response to antiangiogenic therapy: Clinical implications.

M Quintela-Fandino1.   

Abstract

In a recent article in Cell Reports, we described a novel mechanism for acquired resistance against new small-molecule antiangiogenic tyrosine-kinase inhibitors (TKIs). Vascular normalization-inducing TKIs block glycolysis and trigger a nutritional stress response in the tumor compartment that induces a (targetable) switch to mitochondrial metabolism. We discuss the implications for clinical/translational studies and suggest areas for future research.

Entities:  

Keywords:  Antiangiogenics; ME-344; breast cancer; metabolic synthetic lethality; nintedanib; phenformin; resistance

Year:  2016        PMID: 27857979      PMCID: PMC5068174          DOI: 10.1080/23723556.2016.1217368

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN: 2372-3556


  10 in total

Review 1.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation.

Authors:  Sophia Y Lunt; Matthew G Vander Heiden
Journal:  Annu Rev Cell Dev Biol       Date:  2011       Impact factor: 13.827

2.  Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Authors:  Sil Kordes; Michael N Pollak; Aeilko H Zwinderman; Ron A Mathôt; Mariëtte J Weterman; Aart Beeker; Cornelis J Punt; Dick J Richel; Johanna W Wilmink
Journal:  Lancet Oncol       Date:  2015-06-08       Impact factor: 41.316

3.  Relevance of the OCT1 transporter to the antineoplastic effect of biguanides.

Authors:  Eric D Segal; Amber Yasmeen; Marie-Claude Beauchamp; Joshua Rosenblatt; Michael Pollak; Walter H Gotlieb
Journal:  Biochem Biophys Res Commun       Date:  2011-10-02       Impact factor: 3.575

Review 4.  The mighty mouse: genetically engineered mouse models in cancer drug development.

Authors:  Norman E Sharpless; Ronald A Depinho
Journal:  Nat Rev Drug Discov       Date:  2006-08-18       Impact factor: 84.694

Review 5.  Adaptive reciprocity of lipid and glucose metabolism in human short-term starvation.

Authors:  Maarten R Soeters; Peter B Soeters; Marieke G Schooneman; Sander M Houten; Johannes A Romijn
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-10-16       Impact factor: 4.310

Review 6.  Controlling escape from angiogenesis inhibitors.

Authors:  Barbara Sennino; Donald M McDonald
Journal:  Nat Rev Cancer       Date:  2012-10       Impact factor: 60.716

Review 7.  The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.

Authors:  Michalis Mastri; Spencer Rosario; Amanda Tracz; Robin E Frink; Rolf A Brekken; John M L Ebos
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

8.  Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics.

Authors:  Paloma Navarro; Maria J Bueno; Ivana Zagorac; Tamara Mondejar; Jesus Sanchez; Silvana Mourón; Javier Muñoz; Gonzalo Gómez-López; Veronica Jimenez-Renard; Francisca Mulero; Navdeep S Chandel; Miguel Quintela-Fandino
Journal:  Cell Rep       Date:  2016-06-09       Impact factor: 9.423

9.  Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma.

Authors:  Ping Yuan; Koichi Ito; Rolando Perez-Lorenzo; Christina Del Guzzo; Jung Hyun Lee; Che-Hung Shen; Marcus W Bosenberg; Martin McMahon; Lewis C Cantley; Bin Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

10.  Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.

Authors:  Elena Hernández-Agudo; Tamara Mondejar; Maria Luisa Soto-Montenegro; Diego Megías; Silvana Mouron; Jesus Sanchez; Manuel Hidalgo; Pedro Pablo Lopez-Casas; Francisca Mulero; Manuel Desco; Miguel Quintela-Fandino
Journal:  Mol Oncol       Date:  2015-12-22       Impact factor: 6.603

  10 in total
  2 in total

Review 1.  Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Authors:  Jenna L Carter; Katie Hege; Jay Yang; Hasini A Kalpage; Yongwei Su; Holly Edwards; Maik Hüttemann; Jeffrey W Taub; Yubin Ge
Journal:  Signal Transduct Target Ther       Date:  2020-12-18

2.  Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.

Authors:  Denian Wang; Fei Xiao; Zhongxue Feng; Min Li; Lingmiao Kong; Luping Huang; Yong'gang Wei; Hongyu Li; Fei Liu; Haili Zhang; Wei Zhang
Journal:  Breast Cancer Res       Date:  2020-09-29       Impact factor: 6.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.